Literature DB >> 30311388

ClinVar database of global familial hypercholesterolemia-associated DNA variants.

Michael A Iacocca1, Joana R Chora2,3, Alain Carrié4,5, Tomáš Freiberger6,7, Sarah E Leigh8, Joep C Defesche9, C Lisa Kurtz10, Marina T DiStefano11, Raul D Santos12, Steve E Humphries13, Pedro Mata14, Cinthia E Jannes12, Amanda J Hooper15, Katherine A Wilemon16, Pascale Benlian17, Robert O'Connor18, John Garcia19, Hannah Wand20, Lukáš Tichy21, Eric J Sijbrands22, Robert A Hegele1, Mafalda Bourbon2,3, Joshua W Knowles16,20.   

Abstract

Accurate and consistent variant classification is imperative for incorporation of rapidly developing sequencing technologies into genomic medicine for improved patient care. An essential requirement for achieving standardized and reliable variant interpretation is data sharing, facilitated by a centralized open-source database. Familial hypercholesterolemia (FH) is an exemplar of the utility of such a resource: it has a high incidence, a favorable prognosis with early intervention and treatment, and cascade screening can be offered to families if a causative variant is identified. ClinVar, an NCBI-funded resource, has become the primary repository for clinically relevant variants in Mendelian disease, including FH. Here, we present the concerted efforts made by the Clinical Genome Resource, through the FH Variant Curation Expert Panel and global FH community, to increase submission of FH-associated variants into ClinVar. Variant-level data was categorized by submitter, variant characteristics, classification method, and available supporting data. To further reform interpretation of FH-associated variants, areas for improvement in variant submissions were identified; these include a need for more detailed submissions and submission of supporting variant-level data, both retrospectively and prospectively. Collaborating to provide thorough, reliable evidence-based variant interpretation will ultimately improve the care of FH patients.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ClinVar; Clinical Genome Resource; familial hypercholesterolemia; variant interpretation

Mesh:

Substances:

Year:  2018        PMID: 30311388      PMCID: PMC6206854          DOI: 10.1002/humu.23634

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  19 in total

1.  Multiple crm- mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions.

Authors:  H H Hobbs; E Leitersdorf; J L Goldstein; M S Brown; D W Russell
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

Review 2.  Familial hypercholesterolaemia.

Authors:  Joep C Defesche; Samuel S Gidding; Mariko Harada-Shiba; Robert A Hegele; Raul D Santos; Anthony S Wierzbicki
Journal:  Nat Rev Dis Primers       Date:  2017-12-07       Impact factor: 52.329

3.  Using ClinVar as a Resource to Support Variant Interpretation.

Authors:  Steven M Harrison; Erin R Riggs; Donna R Maglott; Jennifer M Lee; Danielle R Azzariti; Annie Niehaus; Erin M Ramos; Christa L Martin; Melissa J Landrum; Heidi L Rehm
Journal:  Curr Protoc Hum Genet       Date:  2016-04-01

4.  Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.

Authors:  Amit V Khera; Hong-Hee Won; Gina M Peloso; Kim S Lawson; Traci M Bartz; Xuan Deng; Elisabeth M van Leeuwen; Pradeep Natarajan; Connor A Emdin; Alexander G Bick; Alanna C Morrison; Jennifer A Brody; Namrata Gupta; Akihiro Nomura; Thorsten Kessler; Stefano Duga; Joshua C Bis; Cornelia M van Duijn; L Adrienne Cupples; Bruce Psaty; Daniel J Rader; John Danesh; Heribert Schunkert; Ruth McPherson; Martin Farrall; Hugh Watkins; Eric Lander; James G Wilson; Adolfo Correa; Eric Boerwinkle; Piera Angelica Merlini; Diego Ardissino; Danish Saleheen; Stacey Gabriel; Sekar Kathiresan
Journal:  J Am Coll Cardiol       Date:  2016-04-03       Impact factor: 24.094

5.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification.

Authors:  Laura M Amendola; Michael O Dorschner; Peggy D Robertson; Joseph S Salama; Ragan Hart; Brian H Shirts; Mitzi L Murray; Mari J Tokita; Carlos J Gallego; Daniel Seung Kim; James T Bennett; David R Crosslin; Jane Ranchalis; Kelly L Jones; Elisabeth A Rosenthal; Ella R Jarvik; Andy Itsara; Emily H Turner; Daniel S Herman; Jennifer Schleit; Amber Burt; Seema M Jamal; Jenica L Abrudan; Andrew D Johnson; Laura K Conlin; Matthew C Dulik; Avni Santani; Danielle R Metterville; Melissa Kelly; Ann Katherine M Foreman; Kristy Lee; Kent D Taylor; Xiuqing Guo; Kristy Crooks; Lesli A Kiedrowski; Leslie J Raffel; Ora Gordon; Kalotina Machini; Robert J Desnick; Leslie G Biesecker; Steven A Lubitz; Surabhi Mulchandani; Greg M Cooper; Steven Joffe; C Sue Richards; Yaoping Yang; Jerome I Rotter; Stephen S Rich; Christopher J O'Donnell; Jonathan S Berg; Nancy B Spinner; James P Evans; Stephanie M Fullerton; Kathleen A Leppig; Robin L Bennett; Thomas Bird; Virginia P Sybert; William M Grady; Holly K Tabor; Jerry H Kim; Michael J Bamshad; Benjamin Wilfond; Arno G Motulsky; C Ronald Scott; Colin C Pritchard; Tom D Walsh; Wylie Burke; Wendy H Raskind; Peter Byers; Fuki M Hisama; Heidi Rehm; Debbie A Nickerson; Gail P Jarvik
Journal:  Genome Res       Date:  2015-01-30       Impact factor: 9.043

6.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

7.  Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Authors:  Keith Nykamp; Michael Anderson; Martin Powers; John Garcia; Blanca Herrera; Yuan-Yuan Ho; Yuya Kobayashi; Nila Patil; Janita Thusberg; Marjorie Westbrook; Scott Topper
Journal:  Genet Med       Date:  2017-05-11       Impact factor: 8.822

8.  Clinically impactful differences in variant interpretation between clinicians and testing laboratories: a single-center experience.

Authors:  Austin Bland; Elizabeth A Harrington; Kyla Dunn; Mitchel Pariani; Julia C K Platt; Megan E Grove; Colleen Caleshu
Journal:  Genet Med       Date:  2017-12-14       Impact factor: 8.822

9.  Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis.

Authors:  Joana Rita Chora; Ana Margarida Medeiros; Ana Catarina Alves; Mafalda Bourbon
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

Review 10.  Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.

Authors:  Leo E Akioyamen; Jacques Genest; Shubham D Shan; Rachel L Reel; Jordan M Albaum; Anna Chu; Jack V Tu
Journal:  BMJ Open       Date:  2017-09-01       Impact factor: 2.692

View more
  19 in total

1.  The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia.

Authors:  Alexey Meshkov; Alexandra Ershova; Anna Kiseleva; Evgenia Zotova; Evgeniia Sotnikova; Anna Petukhova; Anastasia Zharikova; Pavel Malyshev; Tatyana Rozhkova; Anastasia Blokhina; Alena Limonova; Vasily Ramensky; Mikhail Divashuk; Zukhra Khasanova; Anna Bukaeva; Olga Kurilova; Olga Skirko; Maria Pokrovskaya; Valeriya Mikova; Ekaterina Snigir; Alexsandra Akinshina; Sergey Mitrofanov; Daria Kashtanova; Valentin Makarov; Valeriy Kukharchuk; Sergey Boytsov; Sergey Yudin; Oxana Drapkina
Journal:  Genes (Basel)       Date:  2021-01-06       Impact factor: 4.096

2.  Partial LPL deletions: rare copy-number variants contributing towards severe hypertriglyceridemia.

Authors:  Jacqueline S Dron; Jian Wang; Adam D McIntyre; Henian Cao; John F Robinson; P Barton Duell; Priya Manjoo; James Feng; Irina Movsesyan; Mary J Malloy; Clive R Pullinger; John P Kane; Robert A Hegele
Journal:  J Lipid Res       Date:  2019-09-13       Impact factor: 5.922

Review 3.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

4.  Statins for children with familial hypercholesterolemia.

Authors:  Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Serena Tonstad; Albert Wiegman; Euridiki Drogari; Uma Ramaswami
Journal:  Cochrane Database Syst Rev       Date:  2019-11-07

5.  The benign c.344G > A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia.

Authors:  Mika Hori; Atsushi Takahashi; Cheol Son; Masatsune Ogura; Mariko Harada-Shiba
Journal:  Lipids Health Dis       Date:  2020-04-06       Impact factor: 3.876

6.  The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study.

Authors:  Alexey N Meshkov; Alexandra I Ershova; Anna V Kiseleva; Svetlana A Shalnova; Oxana M Drapkina; Sergey A Boytsov
Journal:  J Pers Med       Date:  2021-05-24

7.  Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement.

Authors:  Maria Donata Di Taranto; Carola Giacobbe; Daniela Palma; Gabriella Iannuzzo; Marco Gentile; Ilenia Calcaterra; Ornella Guardamagna; Renata Auricchio; Matteo Nicola Dario Di Minno; Giuliana Fortunato
Journal:  Clin Genet       Date:  2021-08-03       Impact factor: 4.296

8.  Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia.

Authors:  Pei Jun Zhao; Matthew R Ban; Michael A Iacocca; Adam D McIntyre; Jian Wang; Robert A Hegele
Journal:  CJC Open       Date:  2019-07-02

9.  Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.

Authors:  Jacqueline S Dron; Jian Wang; Adam D McIntyre; Michael A Iacocca; John F Robinson; Matthew R Ban; Henian Cao; Robert A Hegele
Journal:  BMC Med Genomics       Date:  2020-02-10       Impact factor: 3.063

10.  Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia.

Authors:  Timothy Lee; Michael A Iacocca; Matthew R Ban; Robert A Hegele
Journal:  CJC Open       Date:  2019-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.